Cardiovascular Risk Reduction with Icosapent Ethyl

To the Editor: In their two articles, Bhatt et al. 1 and Manson et al. 2 (Jan. 3 issue) report opposing results for n−3 fatty acids with respect to cardiovascular risk benefits. However, there is a difference by a factor of 4.75 in the daily doses of n−3 fatty acids that were administered in the two trials: 840 mg versus 3992 mg. These findings are consistent with the results of the Alpha Omega Trial, 3 in which low-dose n−3 fatty acids were ineffective in reducing cardiovascular events. 3 The dose-dependent increases in plasma and tissue levels of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) . . .